Atlas Trials

A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer

Clinical trial NCT02053636 · COMPLETED

Trial details

NCT number
NCT02053636
Sponsor
Institut de Recherches Internationales Servier
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2013-12-01
Primary completion
2017-03-01
Enrollment
76

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.